The medical cannabis company Odi Pharma announces a reverse profit warning following strong revenue growth during October–December 2025. Preliminary figures show revenue of approximately SEK 11 million in the second quarter of the 2025/2026 fiscal year, an increase of 84.3 percent compared with the previous quarter. In the corresponding quarter last year, revenue was SEK 0. The company expects a positive net profit, driven by higher order volumes and more stable operations.The full report will be released on February 26.